Association Between the Number of Invasive Tumor Foci and Axillary Nodal Burden in Multifocal and Multicentric Breast Cancer.
- 1Department of Medical Oncology, Faculty of Medicine, Eskisehir Osmangazi University, 26040 Eskisehir, Türkiye.
Abstract
Multifocal and multicentric (MF/MC) breast cancers are associated with increased axillary lymph node involvement, but the relevance of the number of invasive tumor foci is less clear. This retrospective study included 1087 patients with non-metastatic invasive breast cancer who underwent definitive surgery between 2010 and 2022 without prior neoadjuvant therapy. Patients were grouped as having one, two, or three or more invasive foci; the three-or-more-foci category was used pragmatically to avoid small subgroups at higher focus counts rather than as a data-derived threshold. Multivariable logistic and Cox regression analyses were used to evaluate advanced nodal disease (N2/N3) and disease-free survival (DFS), respectively. N2/N3 disease was present in 18.4%, 19.0%, and 38.2% of patients, respectively (p < 0.001). Three or more foci were independently associated with N2/N3 disease (OR 2.81, 95% CI 1.65-4.79; p < 0.001), whereas two foci were not. At a median follow-up of 113.1 months, 10-year DFS rates were 77.0%, 82.5%, and 55.7%, respectively (log-rank p = 0.003). Three or more foci remained associated with poorer DFS after multivariable adjustment (HR 1.58, 95% CI 1.07-2.33; p = 0.022), whereas two foci were not. A statistically significant difference in OS was not demonstrated (log-rank p = 0.088), although the study may have had limited power for this endpoint. Greater nodal burden and poorer DFS were mainly observed in patients with three or more invasive foci. Focus number may help characterize this heterogeneity within MF/MC disease, although its value beyond total invasive tumor burden remains uncertain.
Related
- Expanding the Boundaries of Breast Conservation: Oncoplastic Surgery in Multifocal and Multicentric Breast Cancer
- Tailoring Escalated Adjuvant Chemotherapy for Multifocal and Multicentric Breast Cancer With Low Tumor Burden.
- Multifocal FDG-avid pancreatic pseudomasses mimicking metastases during pembrolizumab for axillary recurrence of triple-negative breast cancer: a case report of immune-related pancreatitis
- Maximizing cardiopulmonary support as a minimally invasive platform—using peripheral parallel veno-venous and veno-arterial extracorporeal membrane oxygenation and axillary impella 5.5 as a bridge to heart–lung transplantation
- A nomogram integrating ultrasound features of the primary tumor and axillary lymph nodes with clinicopathological factors to predict high axillary lymph node burden in invasive breast cancer
BibTeX
@article{yildiz2026association,
title = {{Association Between the Number of Invasive Tumor Foci and Axillary Nodal Burden in Multifocal and Multicentric Breast Cancer.}},
author = {Bulent Yildiz and Yasemin Sagdic Karateke and Duygu Bayir Garbioglu and Metin Demir},
journal = {Current oncology (Toronto, Ont.)},
year = {2026},
month = oct,
doi = {10.3390/curroncol33100638},
url = {https://europepmc.org/article/MED/42930205},
note = {CC BY},
}
RIS
TY - JOUR
TI - Association Between the Number of Invasive Tumor Foci and Axillary Nodal Burden in Multifocal and Multicentric Breast Cancer.
AU - Bulent Yildiz
AU - Yasemin Sagdic Karateke
AU - Duygu Bayir Garbioglu
AU - Metin Demir
PY - 2026
DA - 2026/10/21
JO - Current oncology (Toronto, Ont.)
DO - 10.3390/curroncol33100638
UR - https://europepmc.org/article/MED/42930205
AB - Multifocal and multicentric (MF/MC) breast cancers are associated with increased axillary lymph node involvement, but the relevance of the number of invasive tumor foci is less clear. This retrospective study included 1087 patients with non-metastatic invasive breast cancer who underwent definitive surgery between 2010 and 2022 without prior neoadjuvant therapy. Patients were grouped as having one, two, or three or more invasive foci; the three-or-more-foci category was used pragmatically to avoid small subgroups at higher focus counts rather than as a data-derived threshold. Multivariable logistic and Cox regression analyses were used to evaluate advanced nodal disease (N2/N3) and disease-free survival (DFS), respectively. N2/N3 disease was present in 18.4%, 19.0%, and 38.2% of patients, respectively (p < 0.001). Three or more foci were independently associated with N2/N3 disease (OR 2.81, 95% CI 1.65-4.79; p < 0.001), whereas two foci were not. At a median follow-up of 113.1 months, 10-year DFS rates were 77.0%, 82.5%, and 55.7%, respectively (log-rank p = 0.003). Three or more foci remained associated with poorer DFS after multivariable adjustment (HR 1.58, 95% CI 1.07-2.33; p = 0.022), whereas two foci were not. A statistically significant difference in OS was not demonstrated (log-rank p = 0.088), although the study may have had limited power for this endpoint. Greater nodal burden and poorer DFS were mainly observed in patients with three or more invasive foci. Focus number may help characterize this heterogeneity within MF/MC disease, although its value beyond total invasive tumor burden remains uncertain.
SN - 1198-0052
SN - 1718-7729
ER -